Welcome to the licensing division of TSOI for the JadiCell™ Adult Donor Multi-Potent Mesenchymal Stem Cells.
The available uses of JadiCell™ for neurological and lung diseases are available for licensing under issued US Patent No.: 9,803,176 B2 and multiple patent pending applications.
Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses
Abstract
Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In another aspect, the isolated cell expresses at least eight cell markers selected from CD29, CD73, CD90, CD146, CD166, SSEA4, CD9, CD44, CD146, or CD105. In another aspect, the isolated cell does not express at least eight cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CDS0, CD80, CD19, CD117, Stro-1, or HLA-DR and are negative for NANOG.
